{
    "Case ID": "051345",
    "Crime_Name": [
        "Patent Infringement Dispute"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent Infringement Dispute"
    ],
    "Legal_Issue": [
        "Whether the term 'medicine' includes mechanical devices used to administer active substances"
    ],
    "Governing_Law": [
        "The Regulations defining 'medicine' as a substance intended or capable of being used for diagnosis, treatment, etc."
    ],
    "Procedural_Stage": [
        "Application for prohibition under the 30-month stay period"
    ],
    "Evidence_Assessment": [],
    "Decision_Outcome": [
        "Application for prohibition dismissed"
    ],
    "Burden_of_Proof": [],
    "Credibility_Factor": [],
    "Legal_Rule": [
        "The term 'medicine' does not include mechanical devices such as inhalers, even if used to administer pharmaceutical substances"
    ],
    "Standard_of_Review": [],
    "Procedural_Issue": [
        "Interpretation of regulatory definition and applicability to mechanical delivery devices"
    ],
    "Grounds_for_Claim": [
        "Glaxo Group Limited claimed patent infringement by Novopharm regarding generic inhalers"
    ],
    "Outcome_on_Merits": [
        "Claim rejected; inhalers not considered 'medicine' under the Regulations"
    ],
    "Decision_Maker": [
        "Court"
    ],
    "Judicial_Review_Outcome": [],
    "Review_Standard": [],
    "Procedural_Fairness_Assessment": [],
    "Key_Evidence_Considered": [
        "Definition of 'medicine', previous case law on pharmaceutical compositions"
    ],
    "Legal_Framework": [
        "Regulations on medicines, patent law"
    ],
    "Applicant_Challenge": [
        "Glaxo sought to prevent approval of generic inhalers based on patent rights"
    ],
    "Court_Result": [
        "Dismissed application; 30-month period continues pending appeals"
    ],
    "Legal_Rule_Source": [
        "Regulations and prior judicial interpretations"
    ],
    "Standard_of_Proof": [],
    "Defendant_Response": [
        "Novopharm argued that inhalers are devices, not medicines, and thus outside the scope of the patent protection under the Regulations"
    ],
    "Evidence_Type": [],
    "Remedy_Requested": [
        "Prevention of regulatory approval for generic inhalers"
    ],
    "Outcome": [
        "Application denied; no injunction granted"
    ],
    "Decision_Authority": [
        "Court"
    ],
    "Remedy_Sought": [
        "Prohibition of approval for generic inhalers"
    ],
    "Resolution_Mechanism": [
        "Judicial determination on statutory interpretation"
    ],
    "Legal_Provision": [
        "Regulations defining 'medicine'"
    ],
    "Authority": [
        "Court"
    ],
    "Claimant_Status": [
        "Glaxo Group Limited as patent holder"
    ],
    "Legal_Provision_Cited": [
        "Regulations on the definition of 'medicine'"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Inhalers do not qualify as 'medicine' under the Regulations"
    ],
    "Applicable_Process": [
        "30-month stay process in patent dispute"
    ],
    "Outcome_of_Review": [],
    "Pending_Relief_or_Application": [
        "Appeals may extend the 30-month period"
    ],
    "Jurisdiction": [],
    "Governing_Rule": [
        "Definition of 'medicine' excludes non-ingestible mechanical devices"
    ]
}